PTC Therapeutics Inc. (PTCT)

42.97
NASDAQ : Health Technology
Prev Close 42.86
Day Low/High 42.19 / 43.69
52 Wk Low/High 27.53 / 48.99
Avg Volume 458.70K
Exchange NASDAQ
Shares Outstanding 58.95M
Market Cap 2.54B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Today's Dead Cat Bounce Stock: PTC Therapeutics (PTCT)

Today's Dead Cat Bounce Stock: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

Interesting PTCT Put And Call Options For March 2016

Interesting PTCT Put And Call Options For March 2016

Investors in PTC Therapeutics Inc saw new options become available this week, for the March 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Strong On High Relative Volume: PTC Therapeutics (PTCT)

Strong On High Relative Volume: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate

Analysts' Actions -- CSX, LinkedIn, Micron and More

Analysts' Actions -- CSX, LinkedIn, Micron and More

Here are Wednesday's top research calls, including upgrades of CSX and LinkedIn.

Insider Trading Alert - PTCT, HES And HTGC Traded By Insiders

Insider Trading Alert - PTCT, HES And HTGC Traded By Insiders

Stocks with insider trader activity include PTCT, HES and HTGC

Trade-Ideas: PTC Therapeutics (PTCT) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: PTC Therapeutics (PTCT) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

November 20th Options Now Available For PTC Therapeutics (PTCT)

November 20th Options Now Available For PTC Therapeutics (PTCT)

Investors in PTC Therapeutics Inc saw new options begin trading today, for the November 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 177 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week of July 17th Options Trading For PTC Therapeutics (PTCT)

First Week of July 17th Options Trading For PTC Therapeutics (PTCT)

Investors in PTC Therapeutics Inc saw new options begin trading this week, for the July 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new July 17th contracts and identified one put and one call contract of particular interest.

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

Santhera -- A Duchenne Drug With Positive Study Results That Few Know About

Santhera -- A Duchenne Drug With Positive Study Results That Few Know About

Santhera is scheduled to meet with the FDA in the next few weeks, after which it expects to submit idebenone for approval by the middle of the year.

Deutsche Compares PTC Therapeutics To Vertex, Boosts Target By $40

Deutsche Compares PTC Therapeutics To Vertex, Boosts Target By $40

Shares of PTC Therapeutics are rising this morning after Deutsche Bank compared the company's earnings power potential to another drugmaker, Vertex, and raised its price target on PTC shares.

Commit To Buy PTC Therapeutics At $40, Earn 18.8% Annualized Using Options

Commit To Buy PTC Therapeutics At $40, Earn 18.8% Annualized Using Options

Investors considering a purchase of PTC Therapeutics Inc shares, but cautious about paying the going market price of $62.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2016 put at the $40 strike, which has a bid at the time of this writing of $6.10.

PTC Therapeutics (PTCT) Is Weak On High Volume Today

PTC Therapeutics (PTCT) Is Weak On High Volume Today

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a weak on high relative volume candidate

PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company

PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company

Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.

Insider Trading Alert - NKSH, PTCT And NNN Traded By Insiders

Insider Trading Alert - NKSH, PTCT And NNN Traded By Insiders

Stocks with insider trader activity include NKSH, PTCT and NNN

Insider Trading Alert - GNMK, PTCT And ALG Traded By Insiders

Insider Trading Alert - GNMK, PTCT And ALG Traded By Insiders

Stocks with insider trader activity include GNMK, PTCT and ALG

Credit Suisse: 8 Biotech and Health Care Stocks Add to Your Portfolio Right Now

Credit Suisse: 8 Biotech and Health Care Stocks Add to Your Portfolio Right Now

Biotechnology and health care in general are some of the hottest areas for investment these days.

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer

To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.

Cramer: R.R. Donnelley Going Higher, 'Be Careful' With PTC Therapeutics

Cramer: R.R. Donnelley Going Higher, 'Be Careful' With PTC Therapeutics

TheStreet's Jim Cramer likes R.R. Donnelley & Sons earnings and lofty dividend yield. As for PTC Therapeutics, beware.

New Lifetime High Reached By PTC Therapeutics (PTCT)

New Lifetime High Reached By PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a new lifetime high candidate

Jim Cramer's Top Stock Picks: GD PTCT RLYP HON PEP

Jim Cramer's Top Stock Picks: GD PTCT RLYP HON PEP

Cramer says he'd buy General Dynamics ahead of earnings and he's a big fan of Honeywell and Pepsico.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer will be watching Europe plue earnings from Halliburton, Starbucks and Verizon, among many others.

Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2

Biotech Investors' Guide and Preview to J.P. Morgan Healthcare Conference: Part 2

The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains

Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains

The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.

PTC Therapeutics (PTCT) Downgraded From Hold to Sell

PTC Therapeutics (PTCT) Downgraded From Hold to Sell

PTC Therapeutics (PTCT) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+. 

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXR, ERIC, HLSS, MIG, ONNN, TPX, UWN, XCRA Downgrades: ATU, BALT, KRNY, LOGM, LRAD, PTCT, VMW Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Trade-Ideas: PTC Therapeutics (PTCT) Is Today's New Lifetime High Stock

Trade-Ideas: PTC Therapeutics (PTCT) Is Today's New Lifetime High Stock

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a new lifetime high candidate

PTC Therapeutics (PTCT) Strong On High Relative Volume Today

PTC Therapeutics (PTCT) Strong On High Relative Volume Today

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate

Trade-Ideas: PTC Therapeutics (PTCT) Is Today's New Lifetime High Stock

Trade-Ideas: PTC Therapeutics (PTCT) Is Today's New Lifetime High Stock

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a new lifetime high candidate

New Lifetime High Reached: PTC Therapeutics (PTCT)

New Lifetime High Reached: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a new lifetime high candidate

TheStreet Quant Rating: D (Sell)